Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma
- Dan T. Vogl
- , Thomas G. Martin
- , Ravi Vij
- , Parameswaran Hari
- , Joseph R. Mikhael
- , David Siegel
- , Ka Lung Wu
- , Michel Delforge
- , Cristina Gasparetto
Research output: Contribution to journal › Article › peer-review
65
Link opens in a new tab
Scopus
citations